arsenic trioxide has been researched along with Lymph Node Metastasis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Chen, Q; Hao, XZ; Liu, JW; Qin, SK; Qu, FL; Qu, T; Sui, GJ; Sun, Y; Zhang, HP | 1 |
| Bedikian, AY; Camacho, LH; Kim, KB; McCullough, C; Papadopoulos, NE | 1 |
3 trial(s) available for arsenic trioxide and Lymph Node Metastasis
| Article | Year |
|---|---|
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
[Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Half-Life; Humans; Injections; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Oxides; Quality of Life; Remission Induction; Survival Rate; Vomiting | 2011 |
A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Choroid Neoplasms; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Survival Rate; Treatment Outcome | 2005 |